Tirzepatide 30MG

What Is Tirzepatide?

Tirzepatide is a synthetic 39-amino-acid peptide and a novel dual receptor agonist that simultaneously targets both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. Often referred to as a “twincretin” in the scientific literature, Tirzepatide represents a structurally and pharmacologically distinct class of incretin-based research compounds.

Unlike single-receptor agonists such as semaglutide, Tirzepatide engages two separate incretin pathways within a single molecule. This dual-mechanism design has made Tirzepatide a subject of significant interest in metabolic research, particularly in studies examining glucose regulation, insulin secretion, and energy homeostasis.

Arma Peptides supplies Tirzepatide 30mg as a lyophilised powder of research-grade purity, manufactured under controlled conditions and intended exclusively for in vitro and in vivo laboratory investigations.

Mechanism of Action

Tirzepatide’s distinguishing characteristic is its balanced dual-receptor engagement. At the GIP receptor, Tirzepatide modulates insulin secretion in a glucose-dependent manner and influences lipid metabolism within adipose tissue. At the GLP-1 receptor, Tirzepatide activates pathways associated with glycaemic control, gastric emptying, and appetite-related signalling in preclinical models.

Research has demonstrated that Tirzepatide’s affinity at the GIP receptor is broadly similar to native GIP, while its activity at the GLP-1 receptor is somewhat lower compared to selective GLP-1 agonists. This differential affinity profile is thought to contribute to Tirzepatide’s observed downstream signalling characteristics in experimental systems, including distinct cAMP activation patterns relative to single-target incretin analogues.

The Tirzepatide molecule is acylated with a C20 fatty diacid moiety to extend its half-life in biological systems, a structural feature that has been characterised in detail across multiple pharmacokinetic studies available in the peer-reviewed literature.

Research Overview

Tirzepatide has been extensively studied in preclinical and early clinical experimental models since its first description in the scientific literature. The compound’s dual-agonism profile has attracted broad research attention, spanning metabolic biology, endocrinology, and receptor pharmacology.

Key findings from published experimental studies include characterisation of Tirzepatide’s receptor-binding kinetics, analysis of insulin secretion dynamics in isolated pancreatic beta-cell preparations, and observations of body composition changes in diet-induced obesity rodent models. Comparative pharmacology studies have also positioned Tirzepatide relative to selective GIP and GLP-1 agonists to delineate receptor-specific contributions to observed outcomes.

Foundational pharmacological and structural data for Tirzepatide are available via PubChem (NIH), with binding and activity annotations held in the ChEMBL database (EMBL-EBI), and additional molecular data indexed at NCBI.

Research Applications

Tirzepatide is used across a range of experimental contexts in the research literature. Documented areas of investigation include:

• Dual GIP/GLP-1 receptor co-activation and comparative downstream cAMP signalling
• Glucose-stimulated insulin secretion (GSIS) assays in pancreatic beta-cell cultures
• Adipogenesis modulation and lipid turnover studies in adipocyte models
• Body composition and energy balance experiments in diet-induced obesity (DIO) animal models
• Receptor selectivity profiling versus selective GIP and GLP-1 reference agonists
• Comparative pharmacokinetic studies examining half-life extension via fatty acid acylation
• Hypothalamic appetite signalling pathway investigations in rodent models

Product Specifications

Storage & Handling

For preservation of research integrity, Tirzepatide 30mg should be stored at –20°C in its original sealed vial, protected from light and moisture. Once reconstituted for experimental use, aliquots should be kept at 4°C and used within a short timeframe in accordance with standard peptide handling protocols. Reconstitution for laboratory purposes is typically performed using sterile water or bacteriostatic water.

All laboratory handling of Tirzepatide must comply with applicable institutional biosafety guidelines and relevant regulatory requirements.

Related Research Peptides

Researchers investigating incretin biology, metabolic signalling, and receptor pharmacology may also find the following Arma Peptides research compounds relevant:

• Retatrutide 30mg — triple GIP/GLP-1/glucagon receptor agonist for multi-incretin pathway research
• Semaglutide 5mg — selective GLP-1 receptor agonist reference compound
• MOTS-C 10mg — mitochondrial-derived peptide studied in metabolic and energy pathway contexts
• NAD+ — coenzyme investigated in cellular energy metabolism and metabolic pathway research

Research Disclaimer

Tirzepatide 30mg is supplied by Arma Peptides strictly for controlled scientific research. Not intended for human or veterinary use. All handling must comply with applicable institutional and regulatory guidelines.